Skip to main content
. 2018 Mar 21;9:127. doi: 10.3389/fneur.2018.00127

Figure 10.

Figure 10

Calculated HR and 95% CIs for the relationship between methylation and PFS benefit from TMZ-containing or TMZ-free therapy in recurrent GBM patients (methylated vs. unmethylated patients).